On Apr. 23, 2018, Medigen Vaccine Biologics and GC Pharma entered an exclusive distribution agreement for GCC’s quadrivalent influenza vaccine, GC Flu Quadrivalent, in Taiwan. GCFlu Quadrivalent was first licensed by South Korean Authority in 2015. It was the second World Health Organization (WHO) prequalified seasonal influenza vaccine to cover against four influenza strains.

MVC will exclusively commercialize and distribute the vaccine using GC Pharma’s final product, or perform fill/finish and distribute the vaccine using MVC’s own brand. This new partnership supports MVC’s strategy to provide people more prophylactic treatment against infectious diseases.

MVC is a cell-based biopharmaceutical company focusing on the development and production of vaccines and biologics. MVC’s business partners include US NIH, US CDC, WHO/UCAB, Taiwan CDC, and Taiwan National Health Research Institute. MVC’s pipeline includes enterovirus A71 vaccine, dengue vaccine, H7N9 influenza mock-up vaccine, biosimilar palivizumab, and other niche products including seasonal flu vaccine, snake antivenom and BCG.